Abstract 344P
Background
Breast cancer imposes a significant regional and global health burden not only due to being the most prevalent malignancy in females in the Middle East and worldwide, but due to the associated substantial morbidity and mortality. Therefore, the determination of the epidemiological features of breast cancer in the Middle East is of prominent interest given the significant resultant burden associated with breast cancer as it enables for the efficient introduction of effective interventions.
Methods
Data on 20,046 female patients of different nationalities and residing in Jordan diagnosed with breast cancer during the period of 2000-2018 were obtained from the Jordan Cancer Registry. Consequently, comprehensive statistical analysis was performed to establish the epidemiological characteristics of breast cancer in Jordan, including the overall survival and crude incidence.
Results
A total of 20,046 female patients with a mean age of 51.5 ± 12.5 years old were included in the analysis. Only 6.54% of the enrolled patients were smokers at the time of diagnosis. Breast cancer was more commonly affecting the left breast, 46.9% of the patients, than the right breast, 43.5% of the patients, whereas 1.18% of the patients had breast cancer bilaterally. The upper outer quadrant of the breast was the most commonly reported site of tumour location. Moderately differentiated carcinoma was the most commonly encountered grade in 31.4% of the patients, whereas 28.9% had poorly differentiated carcinoma. Regional spread to the lymph nodes was observed in 19.0% of the sample and 13.1% of the patients had distant metastasis, while localized breast cancer was noted in 16.6% of the patients. A statistically significant increase in the crude incidence of breast cancer in females has been observed in Jordan over the 18 years period with a crude incidence estimated effect of 0.46 (P-value<0.001). The overall survival rate was determined to be 95.8%, 83.2%, and 62.8% at 1-year, 3-year, and 5-year interval, respectively.
Conclusions
Breast cancer in Jordan imposes a significant burden due to the significant increase in the crude incidence over the 18-year period, and thus mandating vigorous and vigilant screening and preventative measures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study
Presenter: Yue Chai
Session: Poster session 03
361P - A phase II study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2- locally advanced breast cancer
Presenter: Jing Wu
Session: Poster session 03
362P - CYBERNEO trial: Update of results at 14 years of follow-up
Presenter: Syrine Ben Dhia
Session: Poster session 03
363P - High adipocytokines and IL-18bp serum levels are associated with lower objective response rate after neoadjuvant treatment in breast cancer patients with metabolic syndrome
Presenter: Larissa Mont'Alverne Arruda
Session: Poster session 03
365P - Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study
Presenter: Baocheng Wang
Session: Poster session 03
366P - Artificial intelligence (AI)-powered assessment of complete and intense human epidermal growth factor receptor 2 (HER2)-positive tumor cell proportion in breast cancer: Predicting fluorescence in situ hybridization (FISH) positivity and response to HER2-targeted therapy
Presenter: Minsun Jung
Session: Poster session 03
367P - Sentinel lymph node biopsy (SLNB) in patients with locally advanced breast cancer (LABC): Descriptive, inferential and survival analysis
Presenter: Johanna Espejo Niño
Session: Poster session 03
368P - Impact of PET-CT-determined sarcopenia on survival and pathological complete response in breast cancer patients with neoadjuvant chemotherapy
Presenter: Gözde Tahtaci
Session: Poster session 03
369P - The impact of germline BRCA mutations in locally advanced, triple-negative breast cancer (TNBC) treated with platinum- based neoadjuvant chemotherapy
Presenter: Hadar Goldvaser
Session: Poster session 03
370P - LYMPHA surgery to reduce lymphedema following axillary node clearance: A new study at a London plastics centre
Presenter: Dorian Hobday
Session: Poster session 03